These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 24555957)

  • 1. The problem of unreasonably high pharmaceutical fees for patients in Chinese hospitals: a system dynamics simulation model.
    Li M; Zhu Y; Xue C; Liu Y; Zhang L
    Comput Biol Med; 2014 Apr; 47():58-65. PubMed ID: 24555957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypharmacy: its cost burden and barrier to medical care in a drug-oriented health care system.
    Isenalumhe AE; Oviawe O
    Int J Health Serv; 1988; 18(2):335-42. PubMed ID: 3132431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing.
    Tang W; Xie J; Lu Y; Liu Q; Malone D; Ma A
    J Med Econ; 2018 Apr; 21(4):326-339. PubMed ID: 29139303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
    Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
    J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug sales bring huge profits, and scrutiny, to cancer doctors: insurers and experts see high costs and conflicts.
    Abelson R
    N Y Times Web; 2003 Jan; ():A1, 18. PubMed ID: 12647757
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
    Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
    J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug prices.
    AIDS Policy Law; 1996 Dec; 11(22):12. PubMed ID: 11364060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends in drug prescribing rates and costs in New Zealand.
    Malcolm LA; Mehl A
    N Z Med J; 1988 May; 101(845):233-6. PubMed ID: 3368132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost containment: Europe. Germany.
    Burchardi H; Schuster HP; Zielmann S
    New Horiz; 1994 Aug; 2(3):364-74. PubMed ID: 8087598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charging for hospital pharmaceutical services: product cost, per diem fees and fees for special clinical services.
    Smith WE; Weiblen JW
    Am J Hosp Pharm; 1979 Mar; 36(3):355-9. PubMed ID: 420228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Containing medicines costs in the private sector--the example of a medical benefit scheme.
    Hukins G; Boyce D
    S Afr Med J; 1990 Aug; 78(3):152-4. PubMed ID: 2116045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative assessment of the referral system at district level in Zimbabwe: implications on efficiency and effective delivery of health services.
    Hongoro C; Musonza TG; Macq J; Anozie A
    Cent Afr J Med; 1998 Apr; 44(4):93-7. PubMed ID: 9810401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Opinion of primary care physicians from Ourense on various features of the pharmaceutical prescription].
    Díaz Grávalos GJ; Palmeiro Fernández G; Núnñez Masid E; Casado Górriz I
    Rev Esp Salud Publica; 2001; 75(4):361-73. PubMed ID: 11693074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differences in costs to hospitals and prices to patients for pharmaceutical products and services.
    Gillies RW; Winship HW
    Hosp Formul; 1976 Apr; 11(4):189-91, 195-8. PubMed ID: 1026683
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charging for hospital pharmaceutical services: combined product-service per diem fees.
    Dirks I; Pang FJ
    Am J Hosp Pharm; 1979 Mar; 36(3):363-5. PubMed ID: 420230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical doctors profile in Ethiopia: production, attrition and retention. In memory of 100-years Ethiopian modern medicine & the new Ethiopian millennium.
    Berhan Y
    Ethiop Med J; 2008 Jan; 46 Suppl 1():1-77. PubMed ID: 18709707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.